State Street SPDR S&P Pharmaceuticals ETF
XPH
74 hedge funds and large institutions have $286M invested in State Street SPDR S&P Pharmaceuticals ETF in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
56% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 18
7% more funds holding
Funds holding: 69 → 74 (+5)
5% more call options, than puts
Call options by funds: $445K | Put options by funds: $424K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11.16% less ownership
Funds ownership: 70.43% → 59.26% (-11%)
14% less capital invested
Capital invested by funds: $332M → $286M (-$46.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
U
UBS
Zurich,
Switzerland
|
+$7.93M |
| 2 |
CA
Cumberland Advisors
Sarasota,
Florida
|
+$4.15M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.37M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.32M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$975K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$35.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$34.4M |
| 3 |
AP
Advisors Preferred
Rockville,
Maryland
|
-$1.19M |
| 4 |
NCM
Niemann Capital Management
Stateline,
Nevada
|
-$892K |
| 5 |
PG
PEAK6 Group
Chicago,
Illinois
|
-$680K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PG
76
PEAK6 Group
Chicago,
Illinois
| – | -$680K | -13,100 | Closed |
|
77
Jane Street
New York
| – | -$432K | -8,330 | Closed |
|
|
CC
78
Columbia Capital
Fullerton,
California
| – | -$313K | -6,024 | Closed |
|
79
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$73K | -1,400 | Closed |
|
|
W
80
Wealthfront
Palo Alto,
California
| – | -$1K | -24 | Closed |
|
XPH Hedge Fund Activity: Q3 2014 in Review
74 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2014, worth a combined $286M — down 14% from $332M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new XPH positions and 6 closed out — a net gain of 5 holders — while 28 added to existing stakes and 18 trimmed.
The largest buyer was UBS, adding an estimated $7.93M. The largest seller was Goldman Sachs, cutting an estimated $35.3M.
- 74 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2014, up from 69 in Q2 2014.
- Funds reported $286M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2014, down 14% quarter-over-quarter.
- 11 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2014 and 6 closed out, a net change of +5 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2014 was UBS, an estimated $7.93M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2014 was Goldman Sachs, an estimated $35.3M sold.
Based on aggregated 13F filings for Q3 2014.